Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer

Xianjun Fang, Douglas Gaudette, Tatsuro Furui, Muling Mao, Veronica Estrella, Astrid Eder, Terri Pustilnik, Takayo Sasagawa, Ruthie Lapushin, Shiangxing Yu, Robert B. Jaffe, Jon R. Wiener, James R. Erickson, Gordon Mills

Research output: Contribution to journalArticle

195 Citations (Scopus)

Abstract

Levels of lysophosphatidic acid (LPA) and lysophosphatidylcholine (LPC) are elevated in the plasma and ascites of ovarian cancer patients, but not in most other tumor types. LPA increases cell proliferation, cell survival, resistance to cisplatin, cell shrinkage, and production of vascular endothelial growth factor, urokinase plasminogen activator, and LPA itself in ovarian cancer cells, but not in normal ovarian surface epithelial cells. PSP24 and members of the endothelial differentiation gene (EDG) family (EDG1, EDG2, EDG4, and EDG7) of G protein-coupled receptors mediate LPA signaling. Ovarian cancer cell lines do not express EDG1 mRNA, have variable EDG2 mRNA and protein levels, and frequently exhibit elevated levels of EDG4 mRNA and protein, suggesting that EDG4 may contribute to the deleterious effects of LPA in ovarian cancer. In contrast, activation of the EDG2 LPA receptor on ovarian cancer cells may lead to apoptosis and counter the effects of other LPA receptors. Thus, the development of agonists and antagonists for the appropriate spectrum of LPA receptors may alter proliferation, apoptosis, or response to therapy of ovarian cancer cells. Indeed, over 60% of all current drugs target the G protein-coupled family of receptors, making the LPA receptor family a 'drugable' target. LPC, although not as thoroughly studied, increases cellular proliferation and mediates multiple other functions through unique signaling pathways.

Original languageEnglish (US)
Pages (from-to)188-208
Number of pages21
JournalAnnals of the New York Academy of Sciences
Volume905
StatePublished - May 23 2000
Externally publishedYes

Fingerprint

Lysophospholipids
Lysophosphatidic Acid Receptors
Ovarian Neoplasms
Intercellular Signaling Peptides and Proteins
Cells
Neoplasm Metastasis
Lysophosphatidylcholines
Messenger RNA
G-Protein-Coupled Receptors
Apoptosis
Cell Proliferation
Plasminogen Activators
Urokinase-Type Plasminogen Activator
Cell proliferation
GTP-Binding Proteins
Vascular Endothelial Growth Factor A
Cisplatin
Tumors
Ascites
Proteins

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • History and Philosophy of Science

Cite this

Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer. / Fang, Xianjun; Gaudette, Douglas; Furui, Tatsuro; Mao, Muling; Estrella, Veronica; Eder, Astrid; Pustilnik, Terri; Sasagawa, Takayo; Lapushin, Ruthie; Yu, Shiangxing; Jaffe, Robert B.; Wiener, Jon R.; Erickson, James R.; Mills, Gordon.

In: Annals of the New York Academy of Sciences, Vol. 905, 23.05.2000, p. 188-208.

Research output: Contribution to journalArticle

Fang, X, Gaudette, D, Furui, T, Mao, M, Estrella, V, Eder, A, Pustilnik, T, Sasagawa, T, Lapushin, R, Yu, S, Jaffe, RB, Wiener, JR, Erickson, JR & Mills, G 2000, 'Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer', Annals of the New York Academy of Sciences, vol. 905, pp. 188-208.
Fang, Xianjun ; Gaudette, Douglas ; Furui, Tatsuro ; Mao, Muling ; Estrella, Veronica ; Eder, Astrid ; Pustilnik, Terri ; Sasagawa, Takayo ; Lapushin, Ruthie ; Yu, Shiangxing ; Jaffe, Robert B. ; Wiener, Jon R. ; Erickson, James R. ; Mills, Gordon. / Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer. In: Annals of the New York Academy of Sciences. 2000 ; Vol. 905. pp. 188-208.
@article{95df23dbe5db4cfdbcb46c898f065473,
title = "Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer",
abstract = "Levels of lysophosphatidic acid (LPA) and lysophosphatidylcholine (LPC) are elevated in the plasma and ascites of ovarian cancer patients, but not in most other tumor types. LPA increases cell proliferation, cell survival, resistance to cisplatin, cell shrinkage, and production of vascular endothelial growth factor, urokinase plasminogen activator, and LPA itself in ovarian cancer cells, but not in normal ovarian surface epithelial cells. PSP24 and members of the endothelial differentiation gene (EDG) family (EDG1, EDG2, EDG4, and EDG7) of G protein-coupled receptors mediate LPA signaling. Ovarian cancer cell lines do not express EDG1 mRNA, have variable EDG2 mRNA and protein levels, and frequently exhibit elevated levels of EDG4 mRNA and protein, suggesting that EDG4 may contribute to the deleterious effects of LPA in ovarian cancer. In contrast, activation of the EDG2 LPA receptor on ovarian cancer cells may lead to apoptosis and counter the effects of other LPA receptors. Thus, the development of agonists and antagonists for the appropriate spectrum of LPA receptors may alter proliferation, apoptosis, or response to therapy of ovarian cancer cells. Indeed, over 60{\%} of all current drugs target the G protein-coupled family of receptors, making the LPA receptor family a 'drugable' target. LPC, although not as thoroughly studied, increases cellular proliferation and mediates multiple other functions through unique signaling pathways.",
author = "Xianjun Fang and Douglas Gaudette and Tatsuro Furui and Muling Mao and Veronica Estrella and Astrid Eder and Terri Pustilnik and Takayo Sasagawa and Ruthie Lapushin and Shiangxing Yu and Jaffe, {Robert B.} and Wiener, {Jon R.} and Erickson, {James R.} and Gordon Mills",
year = "2000",
month = "5",
day = "23",
language = "English (US)",
volume = "905",
pages = "188--208",
journal = "Annals of the New York Academy of Sciences",
issn = "0077-8923",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer

AU - Fang, Xianjun

AU - Gaudette, Douglas

AU - Furui, Tatsuro

AU - Mao, Muling

AU - Estrella, Veronica

AU - Eder, Astrid

AU - Pustilnik, Terri

AU - Sasagawa, Takayo

AU - Lapushin, Ruthie

AU - Yu, Shiangxing

AU - Jaffe, Robert B.

AU - Wiener, Jon R.

AU - Erickson, James R.

AU - Mills, Gordon

PY - 2000/5/23

Y1 - 2000/5/23

N2 - Levels of lysophosphatidic acid (LPA) and lysophosphatidylcholine (LPC) are elevated in the plasma and ascites of ovarian cancer patients, but not in most other tumor types. LPA increases cell proliferation, cell survival, resistance to cisplatin, cell shrinkage, and production of vascular endothelial growth factor, urokinase plasminogen activator, and LPA itself in ovarian cancer cells, but not in normal ovarian surface epithelial cells. PSP24 and members of the endothelial differentiation gene (EDG) family (EDG1, EDG2, EDG4, and EDG7) of G protein-coupled receptors mediate LPA signaling. Ovarian cancer cell lines do not express EDG1 mRNA, have variable EDG2 mRNA and protein levels, and frequently exhibit elevated levels of EDG4 mRNA and protein, suggesting that EDG4 may contribute to the deleterious effects of LPA in ovarian cancer. In contrast, activation of the EDG2 LPA receptor on ovarian cancer cells may lead to apoptosis and counter the effects of other LPA receptors. Thus, the development of agonists and antagonists for the appropriate spectrum of LPA receptors may alter proliferation, apoptosis, or response to therapy of ovarian cancer cells. Indeed, over 60% of all current drugs target the G protein-coupled family of receptors, making the LPA receptor family a 'drugable' target. LPC, although not as thoroughly studied, increases cellular proliferation and mediates multiple other functions through unique signaling pathways.

AB - Levels of lysophosphatidic acid (LPA) and lysophosphatidylcholine (LPC) are elevated in the plasma and ascites of ovarian cancer patients, but not in most other tumor types. LPA increases cell proliferation, cell survival, resistance to cisplatin, cell shrinkage, and production of vascular endothelial growth factor, urokinase plasminogen activator, and LPA itself in ovarian cancer cells, but not in normal ovarian surface epithelial cells. PSP24 and members of the endothelial differentiation gene (EDG) family (EDG1, EDG2, EDG4, and EDG7) of G protein-coupled receptors mediate LPA signaling. Ovarian cancer cell lines do not express EDG1 mRNA, have variable EDG2 mRNA and protein levels, and frequently exhibit elevated levels of EDG4 mRNA and protein, suggesting that EDG4 may contribute to the deleterious effects of LPA in ovarian cancer. In contrast, activation of the EDG2 LPA receptor on ovarian cancer cells may lead to apoptosis and counter the effects of other LPA receptors. Thus, the development of agonists and antagonists for the appropriate spectrum of LPA receptors may alter proliferation, apoptosis, or response to therapy of ovarian cancer cells. Indeed, over 60% of all current drugs target the G protein-coupled family of receptors, making the LPA receptor family a 'drugable' target. LPC, although not as thoroughly studied, increases cellular proliferation and mediates multiple other functions through unique signaling pathways.

UR - http://www.scopus.com/inward/record.url?scp=0034015046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034015046&partnerID=8YFLogxK

M3 - Article

C2 - 10818454

AN - SCOPUS:0034015046

VL - 905

SP - 188

EP - 208

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

ER -